OliX Pharmaceuticals, Inc (KOSDAQ:226950)

OliX Pharmaceuticals Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	7,810	3,883	11,983	4,930	34,337	11,329
Short-Term Investments	-	-	10,000	53,000	15,000	55,000
Trading Asset Securities	-	8,531	3,942	3,941	420.68	1,782
Cash & Short-Term Investments	7,810	12,414	25,925	61,872	49,757	68,111
Cash Growth	-68.05%	-52.11%	-58.10%	24.35%	-26.95%	91.64%
Accounts Receivable	12,789	0	3,558	53.23	-	-
Other Receivables	843.59	907.84	1,419	996.88	272.13	159.18
Receivables	13,633	907.84	4,977	1,050	491.49	446.57
Inventory	512.78	554.26	468.41	657.17	374.13	304.17
Prepaid Expenses	1,040	1,370	244.9	1,367	1,480	7.13
Other Current Assets	36.18	287.98	526.86	99	136.92	178.26
Total Current Assets	23,031	15,534	32,142	65,046	52,240	69,047
Property, Plant & Equipment	50,283	51,385	43,910	37,232	31,525	6,180
Long-Term Investments	765.38	1,986	23,481	26,809	0.5	0.45
Other Intangible Assets	1,555	1,705	1,981	2,107	2,134	2,529
Other Long-Term Assets	456.29	639.62	1,312	1,458	772.05	820.53
Total Assets	76,090	71,249	102,825	132,651	86,672	78,577
Accrued Expenses	378.04	488.52	465.36	358.62	297.85	80.04
Short-Term Debt	4,079	13,441	-	-	-	-
Current Portion of Long-Term Debt	3,571	3,572	-	19,230	16,405	-
Current Portion of Leases	349.76	745.85	1,065	939.87	487.8	258.63
Current Income Taxes Payable	6.21	53.77	-	-	-	-
Other Current Liabilities	15,902	11,759	5,033	19,014	23,174	4,150
Total Current Liabilities	24,286	30,060	6,563	39,543	40,365	4,488
Long-Term Debt	19,643	21,428	35,362	20,000	20,326	14,011
Long-Term Leases	-	5.38	2,930	3,826	51.69	257
Long-Term Deferred Tax Liabilities	-	-	-	-	-	1,647
Other Long-Term Liabilities	7,976	867.98	7,634	3,080	6,296	12,597
Total Liabilities	52,713	52,777	52,489	66,449	67,265	33,227
Common Stock	9,900	9,230	8,010	6,852	6,852	6,771
Additional Paid-In Capital	204,630	175,533	157,177	151,895	92,908	91,128
Retained Earnings	-197,372	-167,785	-122,910	-103,224	-84,303	-54,379
Comprehensive Income & Other	5,556	871.87	7,141	8,885	3,064	1,765
Total Common Equity	22,713	17,849	49,418	64,407	18,521	45,286
Minority Interest	663.88	623.76	481.45	295.16	886.27	65.31
Shareholders' Equity	23,377	18,473	50,336	66,203	19,407	45,351
Total Liabilities & Equity	76,090	71,249	102,825	132,651	86,672	78,577
Total Debt	27,643	39,192	39,357	43,996	37,271	14,527
Net Cash (Debt)	-19,833	-26,778	-13,433	17,876	12,487	53,584
Net Cash Growth	-	-	-	43.16%	-76.70%	51.72%
Net Cash Per Share	-1088.80	-1589.86	-930.93	1304.50	912.36	4074.15
Filing Date Shares Outstanding	19.8	18.46	16.02	13.7	13.7	13.54
Total Common Shares Outstanding	19.8	18.46	16.02	13.7	13.7	13.54
Working Capital	-1,255	-14,526	25,578	25,502	11,874	64,559
Book Value Per Share	1147.17	966.92	3084.79	4700.19	1351.59	3344.07
Tangible Book Value	21,159	16,144	47,437	62,300	16,387	42,756
Tangible Book Value Per Share	1068.65	874.55	2961.16	4546.39	1195.84	3157.30
Land	25,460	25,460	25,740	25,740	25,740	988.21
Buildings	23,059	23,033	3,354	3,354	3,354	3,115
Machinery	7,271	7,425	6,436	5,518	4,427	3,330
Construction In Progress	-	-	8,948	1,239	71.73	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.